Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief

12 October 2026 · By · Wire by Fusion42

Published

12 October 2026

Topic

operational-macro

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 12 October 2026 · Fusion42 review

Bausch + Lomb CEO Brent Saunders has stepped down by mutual agreement, with Chairman Thomas Appio appointed as interim CEO. The company expects to raise its 2026 adjusted EBITDA forecast based on preliminary third-quarter results, with updated forecasts due October 28.

This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it.

◆ ◆ The Wire takeaway

Leadership turnover at Bausch + Lomb signals potential strategic shifts; you should watch for updated forecasts on October 28 that could open new partnership or investment opportunities in eye care. Interim leadership from within suggests continuity but also a chance to revisit your positioning with the company now.

◆ Coverage

3 sources · 12 Oct 2026

◆ Related on Wire

◆ Topics

Healthexecutive-changeearnings-forecastbausch-lombhealthcare